Factbox: Fat, not muscle: drugmakers in race for next weight-loss breakthrough
Veru Inc reports results for the quarter ended December 31 - Earnings Summary
Veru Inc expected to post a loss of 8 cents a share - Earnings Preview
Veru Inc expected to post a loss of 8 cents a share - Earnings Preview
Veru's experimental drug helps Wegovy patients preserve muscle in study (updated)
Veru's muscle preserving drug meets main goal in mid-stage study
Brief: Veru Announces The Sale Of The FC2 Female Condom Business
Veru Inc reports results for the quarter ended September 30 - Earnings Summary
Veru Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Veru Inc On Aug 19 Delivered Notice To Jefferies To Terminate Open Market Sales Agreement
Veru Inc reports results for the quarter ended in June - Earnings Summary
Brief: Veru Q3 Revenue USD 4 Million Vs. IBES Estimate USD 3.5 Million
Veru Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Veru Says Approved Increase In Number Of Directors Constituting The Board To Seven
Brief: Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
Veru Inc reports results for the quarter ended in March - Earnings Summary
Brief: Veru Q2 Revenue USD 4.1 Million
Veru Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Veru Enrolls First Patients In Phase 2B Clinical Trial Of Enobosarm And Semaglutide Combination For High Quality Weight Loss